Tuberculosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TNF 0
• IL-1 0
• IL-6 0
• IL-17 0
• STING 0
• NLRP3 0
• STAT3 0
• HMGB1 0
• JAK 0
• PD-1 0
• PI3K 0
• TLR4 0
• TP53 0
• TYK2 0
• AKT 0
• CTLA-4 0
• IL-23 0
• mTOR 0
• NRF2 0
• PPAR 0
• SIRT1 0
• CCR5 0
• CD40 0
• EGFR 0
• MAPK 0
• PD-L1 0
• ABL1 0
• AMPK 0
• CD20 0
• COX-2 0
• GPX4 0
• JNK 0
• TFEB 0
• TREM2 0
• VEGF 0
• YAP 0
• ALK 0
• ATM 0
• AXL 0
• BCL-2 0
• BRAF 0
• CD38 0
• FTO 0
• HDAC 0
• HIF-1 0
• HSP90 0
• IL-15 0
• IL-4 0
• MMP-9 0
• NOTCH3 0
• NTRK 0
• PDE4 0
• PKM2 0
• PRMT5 0
• PTEN 0
• STK11 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

  NCT06192160· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 2 Nov 2026

  “Temporarily Closed (Paused) to Accrual.”Registry text, quoted unchanged. Source

• Suspended

  Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

  NCT02354014· Janssen Research & Development, LLC· Updated 17 Sept 2026

  “As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure”Registry text, quoted unchanged. Source

• Withdrawn

  1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

  NCT06191692· Freundeskreis Für Internationale Tuberkulosehilfe e.V· Updated 9 Sept 2026

  “Lack of Rifapentine”Registry text, quoted unchanged. Source

• Terminated

  Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

  NCT04518228· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 26 Aug 2026

  “The study was closed to accrual early based on Study Monitoring Committee review indicating that the study objectives had either been achieved or could not be met within a reasonable timeframe for the then-open arms.”Registry text, quoted unchanged. Source

• Suspended

  Effectiveness and Cost-Effectiveness of Depression Treatment for Individuals With TB in South Africa

  NCT05091580· New York State Psychiatric Institute· Updated 26 Aug 2026

  “Interruption in funding; Planned restart: October 2026”Registry text, quoted unchanged. Source

• Suspended

  Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

  NCT04694586· University Hospital, Linkoeping· Updated 17 Aug 2026

  “Suspended 15th of Nov 2023 due to conditions affecting recruitment process.”Registry text, quoted unchanged. Source

• Withdrawn

  Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

  NCT05539989· International Maternal Pediatric Adolescent AIDS Clinical Trials Group· Updated 17 Aug 2026

  “The study is no longer moving forward due to the changing TB vaccine landscape.”Registry text, quoted unchanged. Source

• Suspended

  Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

  NCT07517445· Gates Medical Research Institute· Updated 10 Aug 2026

  “A temporary precautionary pause in enrolment into all arms of the trial was implemented on 21 July 2026, due to emerging hepatic safety signal. A protocol amendment is currently underway.”Registry text, quoted unchanged. Source

• Terminated

  Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

  NCT04311502· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 8 Jul 2026

  “Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks.”Registry text, quoted unchanged. Source

• Terminated

  Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis

  NCT04575519· Fundació Institut Germans Trias i Pujol· Updated 1 Jun 2026

  “The impact of the COVID-19 pandemic on TB diagnosis affected greatly the recruitment rate and posed challenges to the trial's timeline, consuming the funding needed to continue the enrolment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

  NCT04926922· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

  NCT06192160· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

  NCT03568383· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

  NCT07124559· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women

  NCT07069582· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Re-evaluating the Duration in Children of TB Treatment

  NCT07656012· University of Wisconsin, Madison· Source

• Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

  NCT00814827· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

  NCT07209761· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

  NCT07163143· University College, London· Source

• Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

  NCT06568484· Johns Hopkins University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Organoids 5
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 25
• Gene Expression Profiling 103
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 133
• Exome Sequencing 5
• Proteomics 47
• Metabolomics 39
• Mass Spectrometry 16
• Flow Cytometry 16
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 84
• Machine Learning 102
• Deep Learning 40
• Cohort Studies 101
• Genome-Wide Association Study 12

• Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.

  Clin Transl Sci, Aug 2026

• Adult Onset of MSMD Caused by IL-12Rβ1 Variants: Report of a Young Woman with NTM Infection Lacking Bacille Calmette-Guérin (BCG)-induced Diseases.

  J Clin Immunol, Apr 2026

• Recurrent pulmonary tuberculosis in a child with primary ciliary dyskinesia: a rare association.

  Paediatr Int Child Health, Jan 2026

• Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis.

  Pharmacogenomics, Dec 2025

• TYK2 Deficiency Presenting as Refractory Disseminated BCG/Tuberculosis Infection in a Kazakh Child: A Case Report with Genetic Confirmation.

  Genes (Basel), Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.